Research Article Open Access

Development and Validation of a Stability Indicating Reverse Phase HPLC Method for Simultaneous Determination of Etodolac and Paracetamol in Its Tablet Dosage Formulation

Abstract

A simple, sensitive, accurate, HPLC-UV method has been developed for the simultaneous determination of etodolac and paracetamol in presence of their degradation products in tablet combined dosage formulation. Chromatographic separation was achieved successfully by using phenomenex C18 column (150 mm x 4.6 mm, i.d. 5 m particale size) with an optimized mobile phase of ACN:H2O:H3PO4 in the ratio of 500:500:0.25 (v/v/v) pH 3.0 with triethyamine. The mobile phase was run at a flow rate of 1 ml / minute under isocratic conditions with injection volume 10μl and the quantification of etodolac and paracetamol was carried out by UV detector at 274 nm based on peak area maeasurment. The reliability and performance of the proposed method were statistically validated with respect to system suitability, linearity, accuracy, precision (inter-day and intra-day), specificity, and robustness, limit of detection and limit of quantification. The method was found to be linear in the wide working range of 2 to 80μg/ml and 2.5-100μg/ml for both the analyte of interest with correlation coefficient 0.999 and 0.999 for etodolac and paracetamol respectively. The proposed method proved to be selective and suitable for indicating stability study for both etodolac and paracetamol in presence of any degradation product formed under different forced stress conditions (acidic, alkaline, oxidation, thermal and photolytic). The proposed validated method was successfully applied to the analysis of etodolac and paracetamol in their combined dosage form and thus can be routinely used for the simultaneous determination of etodolac and paracetamol when present in combined formulation.

Mithlesh Rajput, Hinna Hamid, Manjeet Aggarwal, Rakesh Kumar Khandal

To read the full article Download Full Article | Visit Full Article